Advanced search×

Primary amenorrhoea in a patient with mosaicism for monosomy X and a derivative X-chromosome.

Genet Couns 21(3):335-42 (2010) PMID 20964126

Primary amenorrhoea is defined as the absence of menstruation in phenotypic women aged 16 years or older, if secondary sexual characteristics are present. X chromosome abnormalities probably comprise about one half of all cases, including Turner syndrome and X chromosome rearrangements. Conventional banding cytogenetic methods might miss the accurate detection of structural chromosome abnormalities. The fluorescence in situ hybridization (FISH) and multicolor FISH techniques are required to interpret specific chromosomal rearrangement. As far as we know, we report the first case with chromosome mosaicism for monosomy X and terminal deletion of Xq26 with duplication of Xp11-->pter. In spite of the fact that a 45,X karyotype was detected in 46% of lymphocytes, she was tall and her secondary sexual characteristics were moderately developed, including breast, pubic and axillary hair stages. Cytogenetic and FISH analyses should be considered for patients presenting primary amenorrhoea even if there are no other clinical features suggestive of chromosome abnormality.

Version: za2963e q8zad q8zbb q8zc1 q8zd5 q8zef q8zf3 q8zg9

Similar articles you may find interesting…

  1. The study design and rationale of the randomized controlled trial: translating COPD guidelines into primary care practice.

    BMC Fam Pract 14(1):56 (2013) PMID 23641803

    We will also examine the use of a patient activation tool - 'MyLungAge' - to prompt patients at risk for or who have COPD to request spirometry confirmation and to request support for smoking cessation if a smoker. DISCUSSION: Using a multi-modal intervention of patient activation and a technology-s...
  2. Recommendations on the use of EEG monitoring in critically ill patients: consensus statement from the neurointensive care section of the ESI...

    Intensive Care Med (2013) PMID 23653183

    EEG monitoring is an important diagnostic tool for specific indications. Further data are necessary to understand its potential for ischemia assessment and coma prognostication....
  3. Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

    J Clin Oncol (2013) PMID 23650408

    lymphopenia (78.0%), neutropenia (76.3%), leukopenia (72.9%), CD4 lymphopenia (66.1%), and thrombocytopenia (22.0%). CONCLUSIONBR is a promising salvage regimen for patients with relapsed or refractory DLBCL after rituximab-containing chemotherapy, warranting further investigation....